Rajtar Małgorzata
Institute of Philosophy and Sociology, Polish Academy of Sciences, Nowy Świat 72, 00-330, Warsaw, Poland.
Soc Sci Med. 2025 Feb;366:117642. doi: 10.1016/j.socscimed.2024.117642. Epub 2024 Dec 19.
Rare diseases have had a special status within European Union (EU) health policy since the late 1990s. According to key EU legal documents, rare disease patients are entitled to the same good quality care as others. These individuals are particularly vulnerable due to the "low prevalence" and "uniqueness" of their disease. To ensure that patients with rare disorders in Europe can access high-quality care in their respective countries, the Council of the European Union (2009) recommended that member states adopt plans or strategies for rare diseases. Poland adopted its first Plan for Rare Diseases in 2021. This article draws from bioethical and social science scholarship on vulnerability as well as ethnographic research that I conducted among people with rare metabolic diseases, their families, health professionals, and patient advocacy groups in Poland between 2016 and 2023. I examine instruments developed within healthcare policies that are tailored to rare diseases, notably the patient passport, which is a site of disjuncture (Appadurai, 1990) embedded in healthcare policies and practices tailored to people with rare diseases. I argue that although such instruments are meant to benefit patients, they almost exclusively focus on the patient's sick body and the needs of health professionals, who are unfamiliar with a given rare disease. Thus, these instruments may engender paternalistic practices and they may contribute to discrimination and stigmatization as well as to the datafication of health vulnerabilities. Furthermore, the focus on inherent vulnerability obscures its other "layers" (Luna, 2009, 2019) or "degrees" (Traianou and Hammersley, 2023).
自20世纪90年代末以来,罕见病在欧盟卫生政策中一直具有特殊地位。根据欧盟的关键法律文件,罕见病患者有权获得与其他人同等的优质护理。由于其疾病的“低患病率”和“独特性”,这些个体特别脆弱。为确保欧洲患有罕见病的患者能够在各自国家获得高质量护理,欧盟理事会(2009年)建议成员国制定罕见病计划或战略。波兰于2021年通过了首个罕见病计划。本文借鉴了关于脆弱性的生物伦理学和社会科学学术研究,以及我在2016年至2023年期间在波兰对患有罕见代谢疾病的患者、他们的家人、卫生专业人员和患者倡导团体进行的人种志研究。我研究了医疗政策中为罕见病量身定制的工具,特别是患者护照,它是嵌入针对罕见病患者的医疗政策和实践中的脱节场所(阿帕杜莱,1990年)。我认为,尽管这些工具旨在使患者受益,但它们几乎完全专注于患者患病的身体以及不熟悉特定罕见病的卫生专业人员的需求。因此,这些工具可能会导致家长式做法,可能会助长歧视和污名化,以及健康脆弱性的数据化。此外,对内在脆弱性的关注掩盖了其其他“层面”(卢娜,2009年、2019年)或“程度”(特拉亚努和哈默斯利,2023年)。